Brachytherapy and surgery versus surgery alone for IB2 (FIGO 2018) cervical cancers: A FRANCOGYN study.


Journal

European journal of obstetrics, gynecology, and reproductive biology
ISSN: 1872-7654
Titre abrégé: Eur J Obstet Gynecol Reprod Biol
Pays: Ireland
ID NLM: 0375672

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 27 05 2023
revised: 17 09 2023
accepted: 22 09 2023
medline: 13 11 2023
pubmed: 3 10 2023
entrez: 3 10 2023
Statut: ppublish

Résumé

Evaluation of the management by first brachytherapy followed by radical hysterectomy (Wertheim type) compared to radical hysterectomy alone (Wertheim type) for the treatment of IB2 cervical cancer. Data from women with histologically proven FIGO stage IB2 cervical cancer treated between April 1996 and December 2016 were retrospectively abstracted from twelve French institutions with prospectively maintained databases. Of the 211 patients with FIGO stage IB2 cervical cancer without lymph node involvement included, 136 had surgical treatment only and 75 had pelvic lymph node staging and brachytherapy followed by surgery. The surgery-only group had significantly more adjuvant treatment (29 vs. 3; p = 0.0002). A complete response was identified in 61 patients (81%) in the brachytherapy group. Postoperative complications were comparable (63,2% vs. 72%, p = 0,19) and consisted mainly of urinary (36vs. 27) and digestive (31 vs 22) complications and lymphoceles (4 vs. 1). Brachytherapy had no benefit in terms of progression-free survival (p = 0.14) or overall survival (p = 0.59). However, for tumors of between 20 and 30 mm, preoperative brachytherapy improved recurrence-free survival (p = 0.0095) but not overall survival (p = 0.41). This difference was not observed for larger tumors in terms of either recurrence-free survival (p = 0.55) or overall survival (p = 0.95). Our study found that preoperative brachytherapy had no benefit for stage IB2 cervical cancers in terms of recurrence-free survival or overall survival. For tumor sizes between 2 and 3 cm, brachytherapy improves progression-free survival mainly by reducing pelvic recurrences without improving overall survival.

Identifiants

pubmed: 37788511
pii: S0301-2115(23)00742-X
doi: 10.1016/j.ejogrb.2023.09.021
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

128-134

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Othman Aissaoui (O)

CHU Lille, Service de chirurgie gynécologique, F-59000 Lille, France; Univ. Lille, CHU Lille, F-59000 Lille, France. Electronic address: othman.aissaoui@chu-lille.fr.

Jérôme Phalippou (J)

CHU Lille, Service de chirurgie gynécologique, F-59000 Lille, France. Electronic address: jerome.phalippou@chru-lille.fr.

Abel Cordoba (A)

Radiation Oncology and Brachytherapy Department, Centre Oscar Lambret, Lille, France. Electronic address: a-cordoba@o-lambret.fr.

Henri Azais (H)

AP-HP.CUP, Service de chirurgie cancérologique gynécologique et du sein, Hôpital Européen Georges-Pompidou, Paris, France. Electronic address: henri.azais@aphp.fr.

Lobna Ouldamer (L)

Department of Gynaecology. CHRU de Tours. Hôpital Bretonneau. INSERM Unit, 1069, 2 boulevard Tonnellé 37044 TOURS, France. Electronic address: louldamer@yahoo.fr.

Pierre Adrien Bolze (PA)

Department of Gynaecologic and Oncologic Surgery and Obstetrics, Centre Hospitalier Universitaire Lyon Sud, Hospices Civils de Lyon, Université Lyon 1, France. Electronic address: pierre-adrien.bolze@chu-lyon.fr.

Marcos Ballester (M)

Department of Gynaecologic and Breast Surgery, Groupe Hospitalier Diaconesses Croix Saint Simon, 125 rue d'Avron, 75020 Paris, France. Electronic address: mballester@hopital-dcss.org.

Cyrille Huchon (C)

APHP. Service de gynécologie & obstétrique, GH Saint-Louis Lariboisière-Fernand Widal, Hôpital Lariboisière, Université de Paris, 2, rue Ambroise Paré, 75010 Paris, France. Electronic address: cyrillehuchon@yahoo.fr.

Camille Mimoun (C)

APHP. Service de gynécologie & obstétrique, GH Saint-Louis Lariboisière-Fernand Widal, Hôpital Lariboisière, Université de Paris, 2, rue Ambroise Paré, 75010 Paris, France. Electronic address: camille.mimoun@aphp.fr.

Cherif Akladios (C)

Department of Gynecologic Surgery, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Lise Lecointre (L)

Department of Gynecologic Surgery, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. Electronic address: lise.lecointre@chru-lille.fr.

Emilie Raimond (E)

Department of Obstetrics and Gynaecology, Alix de Champagne Institute, Centre Hospitalier Universitaire, 45 rue Cognacq-Jay, 51092 Reims, France.

Olivier Graesslin (O)

Department of Obstetrics and Gynaecology, Alix de Champagne Institute, Centre Hospitalier Universitaire, 45 rue Cognacq-Jay, 51092 Reims, France.

Xavier Carcopino (X)

Department of Obstetrics and Gynaecology, Hôpital Nord, APHM, Aix-Marseille University (AMU), Univ Avignon, CNRS, IRD, IMBE UMR 7263, 13397 Marseille, France. Electronic address: xcarco@free.fr.

Vincent Lavoué (V)

Department of Gynaecology, CHU de Rennes, France; INSERM, 1242, COSS, Rennes, Université de Rennes 1, France.

Sofiane Bendifallah (S)

Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France. Electronic address: sofiane.bendifallah@yahoo.fr.

Cyril Touboul (C)

Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France. Electronic address: Cyril.touboul@gmail.fr.

Yohann Dabi (Y)

Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France.

Geoffroy Canlorbe (G)

Department of Gynecologic and Breast Surgery and Oncology, Hôpital la Pitié Salpétrière, AP-HP Paris, France. Electronic address: geoffroy.canlorbe@aphp.fr.

Martin Koskas (M)

Department of Gynaecology and Obstetrics, Hôpital Bichat, AP HP, France. Electronic address: martin.koskas@aphp.fr.

Pauline Chauvet (P)

Department of Gynaecology and Obstetrics, CHU de Clermont Ferrand, France.

Pierre Collinet (P)

CHU Lille, Service de chirurgie gynécologique, F-59000 Lille, France; Univ. Lille, CHU Lille, F-59000 Lille, France. Electronic address: pierre.collinet@chru-lille.fr.

Yohan Kerbage (Y)

CHU Lille, Service de chirurgie gynécologique, F-59000 Lille, France; Univ. Lille, CHU Lille, F-59000 Lille, France. Electronic address: yohan.kerbage@chru-lille.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH